Frank Ahmann, Chief Operating Officer of Symphony Medical, Inc., is a healthcare entrepreneur with nineteen years of experience in developing and commercializing biopharmaceutical products and medical devices. Prior to joining Symphony, Frank was COO of Nephrogenex, Inc., an early stage company applying molecular profiling technologies to develop new therapies for kidney disease; President and CEO of Allvivo, Inc., a company marketing bioreactive surface coatings for medical devices; and COO of Chimeric Therapies, Inc., a developer of stem cell therapeutics to induce immune tolerance in transplant patients. He was also a strategy consultant to various biotechnology start-up ventures in the cardiovascular and oncology sectors. Before his involvement with healthcare start-ups, Frank worked for Baxter International where he held management positions in various areas of increasing responsibility. Directing an international group responsible for building the company's immunotherapy and stem cell transplantation businesses, he spent eight years in Europe before relocating to Southern California to create and manage a new vascular business unit at the company's Cardiovascular Group (now Edwards Lifesciences). From early research stages, Frank has brought to market numerous successful biologics and devices in the areas of hematology, oncology, transplantation medicine, and cardiovascular surgery. He holds a BBA from the University of Texas at Austin and an MBA from Columbia University's Graduate Business School in New York City.